JANET HALL: Open Payments
NPI 1538390687 · PALO ALTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,127 in 85 payments from 32 companies in 2025. Trend: 2023 $0 · 2024 $2,657 · 2025 $2,127
Food & beverage: $2,027Education: $100
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $216 |
| Celgene Corporation | 7 | $171 |
| PFIZER INC. | 5 | $144 |
| GlaxoSmithKline, LLC. | 6 | $133 |
| E.R. Squibb & Sons, L.L.C. | 5 | $123 |
| Novartis Pharmaceuticals Corporation | 4 | $115 |
| Astellas Pharma US Inc | 1 | $100 |
| Incyte Corporation | 3 | $78 |
| Regeneron Healthcare Solutions, Inc. | 2 | $70 |
Products named: REBLOZYL, OPDIVO, FRUZAQLA, IBRANCE, KISQALI, MONJUVI, ICLUSIG, JEMPERLI.
Industry payments across CA — which companies pay providers there.
